WO2000031113A1 - INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN - Google Patents
INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN Download PDFInfo
- Publication number
- WO2000031113A1 WO2000031113A1 PCT/US1999/027244 US9927244W WO0031113A1 WO 2000031113 A1 WO2000031113 A1 WO 2000031113A1 US 9927244 W US9927244 W US 9927244W WO 0031113 A1 WO0031113 A1 WO 0031113A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hsp70
- cells
- cell
- protein
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Definitions
- the present invention relates to the intracellular delivery, preferably the intranuclear delivery, of compounds using the heat shock protein Hsp70.
- Hsps Heat shock proteins
- Hsp70 is one member of the heat shock protein family. (Milner, CM. and Campbell, R.D. Immunogenetics 32:242-251 (1990); Genbank Accession No. M59828).
- One of the most well characterized functions of Hsp70 is to assist in the translocation of proteins across intracellular membranes into different compartments of the cell.
- Intracellular transport activity has been reported for viral proteins such as the HSV- 1 structural protein VP22 (Elliott, et. al., ( 1997) Cell 88:223-233) and the HTV Tat protein (Vives, et. al., (1997) J. Biol. Chem. 272: 16010-16017), as well as peptide sequences derived from Antennapedia homeodomain, fibroblast growth factor (Hawiger, (1997) Curr. Opin. Immun. 9: 189-194), and most recently the neuropeptide galanin (Pooga, et. al., (1998) FASEB J. 12:67-77).
- viral proteins such as the HSV- 1 structural protein VP22 (Elliott, et. al., ( 1997) Cell 88:223-233) and the HTV Tat protein (Vives, et. al., (1997) J. Biol. Chem. 272: 16010-16017), as well as peptide sequences
- Hsps also serve a number of key functions in the immune response, and over the past few years there has been increasing interest in characterizing the nature of Hsps in generating protective immunity.
- a series of recent studies (Roman, et. al., (1996) Immunology 88:487-492; Suzue, et. al, (1996) J. Immunol. 156:873-879) demonstrated that Hsp70 could act as a carrier protein to enable a bound peptide or protein substrate to enter the endosomal compartment and subsequently access the MHC class II processing pathway for exogenous antigens.
- Such treatment with Hsp70-peptide complexes or Hsp70 fusion proteins could elicit cargo-specific proliferative T cell responses.
- Hsp70 a plasma membrane translocation capacity for Hsp70, such an activity has not been directly demonstrated. It has not been shown whether or not Hsp70 could be utilized to deliver proteins across the plasma and nuclear membranes. There exists a need to deliver compounds, such as proteins or DNA, into the cell nucleus to modulate cellular activity.
- Applicants have shown that the human 70 kD heat shock protein can translocate across cell membranes to rapidly gain cytoplasmic and nuclear entry. Furthermore, chimeric proteins composed of Hsp70 peptides fused to amino acids 37-409 of the p50 subunit of NF- ⁇ B (Meyer, R., et. al, PNAS 88:966-970 (1991); Genbank Accession No. M58603) also exhibit this translocation property. Though cellular import activity has been reported for various diverse peptides, intranuclear transport generally requires the presence of specific nuclear localization sequences ("NLS").
- NLS nuclear localization sequences
- an object of the present invention is to provide a carrier for delivery of molecules with biological function into both cellular and nuclear compartments.
- a preferred embodiment of the present invention utilizes Hsp70, or a fragment of Hsp70 as described herein, as a vehicle for directed, noninvasive delivery of molecules, such as proteins or DNA, that may modulate gene expression.
- Hsp70 The 70kD heat shock protein
- NF- ⁇ B a key transcriptional regulator of inflammatory responses
- Applicants herein show that a fusion protein composed of a C- terminal Hsp70 peptide and amino acids 37-409 of the p50 subunit of NF- ⁇ B was directed into the nucleus of cells, could bind DNA specifically, and activated kappa Ig expression and TNF ⁇ production.
- Applicants' invention encompasses the use of Hsp70 as a vehicle for intracytoplasmic and intranuclear delivery of proteins or DNA to modulate gene expression and thereby control immune responses.
- Figure 1 shows various cell types that exhibit differential Hsp70 uptake activity.
- Various cells were treated with lO ⁇ g/ml Hsp70-FITC added to the culture media.
- Human peripheral blood cells were stained with anti-CD 14-PE as a marker for monocytic cells, anti-CD19-PE for B cells, or anti-CD3-PE for T cells. After one hour of incubation at 37°C, cells were washed in PBS, fixed in 2% paraformaldehyde, washed again and re-suspended in PBS for visualization by confocal laser scanning microscopy. Equimolar amounts of BSA-FITC were used in parallel experiments as a control.
- Figure 1 A shows 70Z/3 cells + Hsp70-FITC
- Figure IB shows 70Z/3 cells + BSA-FITC
- Figure 1C shows PBL stained with anti-CD14-PE + Hsp70-FITC
- Figure ID shows PBL stained with anti-CD14-PE + BSA-FITC
- Figure IE shows PBL stained with anti-CD 19-PE + Hsp70-FITC
- Figure IF shows peripheral blood T cells stained with anti-CD3-PE + Hsp70.
- Figure 2 shows the kinetics of Hsp70 cellular uptake.
- Figure 2A shows the kinetics of uptake of Hsp70-FITC by 70Z/3 cells. The cells were incubated at 37°C for various times with 1 uM Hsp70-FITC in complete RPMI. Cells were washed once in PBS to separate free Hsp70-FITC, then re-suspended in PBS and analyzed by fluorimeter. Points were experimental and the curve was fitted by a modified regression program (XLlfit).
- Figure 2B shows the dose effect of Hsp70 on uptake by 70Z/3 cells.
- FIG. 3 shows that intracellular uptake of Hsp70-FITC was not affected by azide but was inhibited at 4°C.
- 70Z/3 cells were either untreated ( Figure 3 A) or pretreated for 30 minutes with 0.05% sodium azide (Figure 3B) before incubation with Hsp70-FITC at 37°C, or were preincubated at 4°C for 30 minutes prior to addition of Hsp70-FITC and an additional one hour of incubation at 4°C (Figure 3C).
- BSA-FITC was added to cells for 1 hour at 37°C as a control ( Figure 3D).
- Figure 4 shows transport of fusion proteins into the cytoplasm and nucleus.
- FITC-labeled fusion proteins consisting of either the C terminal 244 (Hsp70/28-p50) or 92 (Hsp70/10-p50) amino acids of Hsp70, fused to amino acids 37-409 of the p50 subunit of NF-kB, were transported into 70Z/3 cells.
- 70Z/3 cells were treated with full-length Hsp70-FITC ( Figure 4A), Hsp70/28-p50-FITC ( Figure 4B), Hsp70/10- ⁇ 50-FITC ( Figure 4C), or BSA-FITC as a control ( Figure 4D) for 1 hour at 37°C as described.
- FIG. 5 demonstrates that internalized intracellular Hsp70 or Hsp70-p50 remained stable for up to 24 hours.
- Cells were treated with either full-length Hsp70- FITC (Figure 5A) or Hsp70/28-p50-FITC ( Figure 5B) for one hour prior to washing and additional incubation at 37°C for increasing times.
- Cells were harvested at the indicated timepoints, lysed in Laemmli sample buffer, and whole cell lysate proteins were separated by SDS-PAGE. Gels were subjected to fluorimager analysis. Lanes 1: cells untreated; lane 2: no chase; lane 3: 1 hour of chase; lane 4: 2 hours of chase; lane 5: 6 hours of chase; lane 6: 24 hours of chase; lane 7: 4 days of chase.
- Figure 6 shows that internalized Hsp70-p50 fusion proteins exhibited DNA- binding activity. 70Z/3 cells were treated as indicated for one hour prior to lysis and generation of nuclear extracts. EMS A was performed and specific DNA binding complexes were identified by supershift assay with the indicated antibodies.
- Figure 6A lane 1: unstimulated cells control; lane 2: LPS-treated; lane 3: Hsp70-p50-treated; lane 4: Hsp70-p50-treated extracts competed with unlabelled NF- ⁇ B oligo; lane 5: same as lane 4 but competed with unlabelled octamer oligo.
- Lane 6B lane 1 : LPS- treated; lane 2: LPS-treated and supershifted with anti-p50; lane 3: anti-p65; lane 4: anti-c-rel; lane 5: anti-Hsp70; Lanes 6-10, same as lanes 1-5 but using Hsp70-p50 treated extracts.
- Figure 7 shows that Hsp70-p50-treated cells became activated to express surface kappa Ig and produce TNF .
- Figure 7A 70Z/3 cells were treated with 10 ng/ml LPS or 30 ⁇ g/ml Hsp70/10-p50 overnight prior to washing and staining with anti-kappa-FITC and FACS analysis.
- Figure 7B Human peripheral blood lymphocytes were treated with 5 ng/ml LPS or 40 ⁇ g/ml Hsp70/10-p50 or Hsp70/28- p50 for 6 hours, and supernatants were harvested and analyzed for TNF ⁇ levels by ELISA.
- the present invention demonstrates that the heat shock protein Hsp70 is internalized by cells into both the cytoplasm and nucleus in a cell type specific manner. Although the mechanism of uptake is unknown, the data suggest that the binding and internalization of Hsp70 is energy dependent and involves a high capacity receptor.
- Hsp70 cell surface-associated and secreted forms of Hsp70 exist (Multhoff, et al., ( 1996) Cell Stress & Chaperones 1: 167-176) suggests that this protein may function in cell-cell communication, perhaps as a means of transferring cellular protection from environmental stressors by regulating transcription.
- Hsp70 can bind directly to the transactivation domains of both HSF (heat shock factor) (Shi, et al., (1998) Genes Dev.
- HSF heat shock factor
- Hsp70 as a cytoplasmic chaperone can interact with transcription factors such as NF- ⁇ B itself, as well as a myriad cofactors such as Hip, Hop, Hsp40, Hsp90, BAG-1 and others (Demand, et al., (1998) Mol. Cell. Biol. 18:2023-2028).
- Hsp70 release and intercellular transfer of exported Hsp70 has been reported in glial and axonal cells (Hightower, et al., (1989) J. Cell Physiol. 138:257-266); and accumulation of Hsp70 in a variety of human cell lines either by heat shock or by liposomal transfer has been shown to increase cell survival and protect from apoptotic cell death (Lasunskaia, et al., (1997) Apoptosis 2: 156-163). Release of heat shock proteins from cells under harsh or damaging conditions may be a homeostatic mechanism for transfer of a protective stress response to neighboring cells that are unable to mount such a response. In addition, recent reports describing the ability of peptide-bound
- Hsp70 molecules to induce antitumor or antiviral immunity as well as development of memory CTLs support the notion that these proteins might function to convey a protective immune response by providing an antigen presentation function (Blachere, et al, (1997) J. Exp. Med. 186- 1315-1322; Ciupitu, et al., (1998) J. Exp. Med. 187:685-691).
- Applicants submit that endogenous Hsp70 (and associated peptides or proteins) is/are released into the environment by infected or apoptosing cells. These Hsp70 protein complexes would subsequently become available to neighboring cells which may be compromised in their immune capacity, and act as a stimulus to boost or strengthen the immune response.
- Hsp70 as a delivery system has a number of advantages over other previously described protein candidates, including the fact that the protein is of human origin and therefore does not contain foreign (i.e., viral or insect) and potentially immunogenic material. Use of soluble fragments of Hsp70 will potentially reduce immunogenicity further. As Hsp70 is a highly expressed abundant protein, it would likely be well-tolerated in humans, and in fact already plays an immune response role. In addition, the cell type-specificity we observed would allow the targeting of compounds to specific cells of the immune system for more effective regulatory control. And finally, the preferential and long-lived nuclear directed delivery of protein substrates may provide protection from cytoplasmic proteolysis. Our data support the potential use of Hsp70 sequences as a novel tool to deliver molecules that modulate gene expression and subsequently provide i munosuppressive or immunostimulatory control.
- a fusion protein comprising a fragment of Hsp70 joined to amino acids 37-409 of the NF- ⁇ B p50 subunit (the fusion proteins are referred to herein as Hsp70-p50, Hsp70/28-p50, or Hsp70/10-p50).
- Hsp70-p50 the fusion proteins are referred to herein as Hsp70-p50, Hsp70/28-p50, or Hsp70/10-p50.
- the heat shock protein sequence may itself contain transactivation activity.
- Hsp70 is known to bind heat shock factor in the nucleus and interfere with its transactivation activity via the EEVD domain. Since the Hsp70 sequence in the Examples below was cloned C- terminal to amino acids 37-409 of the NF-kB p50 sequence (SEQ ID NO: l), the EEVD domain is potentially available to provide transactivation, or even to interact with other cellular or nuclear cofactors. Closer analysis of the nuclear complex may yield clues as to other possible components with transcriptional activities. Second, p50 homodimers may simply exhibit transactivation activity in particular circumstances. Fujita, et al. ((1992) Genes Dev.
- the present invention encompasses the use of Hsp70, or a fragment of Hsp70, to modulate cellular activity, preferably modulate nuclear activity in a cell or cells, for example the activity of transcription factors.
- nuclear activity encompasses the transcription of nucleic acid molecules in the cell.
- modulate encompasses enhancement, diminishment, activation or inactivation of cellular activity.
- the Hsp70 protein or a fragment thereof may be used alone to modulate cellular activity by transfer into the cytoplasm and/or nucleus of a cell, to treat Hsp70-associated disorders.
- Hsp70-associated disorders refers to any disorder or disease state in which Hsp70 plays a regulatoiy role in the metabolic pathway of that disorder or disease.
- treating refers to the alleviation of symptoms of a particular disorder in a patient, the improvement of an ascertainable measurement associated with a particular disorder, or the prevention of a particular immune response (such as transplant rejection).
- patient refers to a mammal, preferably a human.
- Hsp70 or a fragment of Hsp70, as a chaperone to carry one or more compounds into a cell.
- Hsp70 or a fragment thereof is joined to a compound to form a complex (herein referred to as an "Hsp70 complex" which includes the Hsp70, or fragment thereof, and any compound associated with or joined to the Hsp70 protein or fragment thereof).
- the Hsp70 complex is then provided to a cell or cells, or to the environment surrounding a cell or cells, so that the Hsp70 complex is transported into the cytoplasm and/or nucleus of the cell or cells.
- Hsp70 protein or a fragment thereof include, but are not limited to, proteins, peptides, nucleic acids, and small molecules.
- Nucleic acids or “polynucleotides” includes individual nucleotides as well as DNA and RNA sequences or fragments thereof.
- Disease states which may be treated by Hsp70, fragments thereof, and/or Hsp70 complexes of the present invention include transplant rejection and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, and inflammatory bowel disease, as well as inflammatory diseases, cancer, viral replication diseases and vascular diseases.
- the Hsp70 complexes and pharmaceutical compositions of the present invention are useful in the treatment of transplant rejection (e.g., kidney, liver, heart, lung, pancreas (e.g., islet cells), bone marrow, cornea, small bowel and skin allografts, and heart valve xenografts) and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, juvenile diabetes, asthma, inflammatory bowel disease (Crohn's disease, ulcerative colitus), lupus, diabetes, myasthenia gravis, psoriasis, dermatitis, eczema, seborrhoea, pulmonary inflammation, eye uveitis, hepatitis, Grave's disease, Hashimoto's thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes/mouth), pernicious or immunohaemolytic anaemia, idiopathic adrenal insufficiency, polyglandular autoimmune diseases
- compositions comprising at least one Hsp70 complex comprising a compound that is to be delivered to the cytoplasm and/or nucleus of a cell or cells.
- the Hsp70 complex may be administered alone or with at least one additional active compound, and any pharmaceutically acceptable earner, adjuvant or vehicle.
- Additional active compounds encompasses, but is not limited to, an agent or agents selected from the group consisting of an immunosuppressant, an anti-cancer agent, an anti-viral agent, an anti-inflammatory agent, an anti-fungal agent, an antibiotic, or an anti-vascular hyperproliferation compound.
- pharmaceutically acceptable carrier, adjuvant or vehicle refers to a carrier, adjuvant or vehicle that may be administered to a subject, together with an Hsp70 complex of the present invention, and which does not destroy the pharmacological activity thereof.
- Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, the following: ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems ("SEDDS”) such as d ⁇ - tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
- Cyclodextrins such as ⁇ -, ⁇ - and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- ⁇ - cyclodextrins, or other solubilized derivatives may also be used to enhance delivery of the compounds of the present invention.
- compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
- compositions comprising at least one Hsp70 complex of the present invention may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
- suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as
- compositions of the present invention may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
- suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.
- the present Hsp70 complexes may also be administered liposomally.
- compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, dis integrants, diluents and lubricants such as those known in the art.
- the present compounds may also be delivered through the oral cavity by sublingual and/or buccal administration.
- Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used.
- Exemplary compositions include those formulating the present Hsc70 complexes with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG).
- Such formulations may also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g.,
- Lubricants may also be added for ease of fabrication and use.
- compositions for nasal aerosol or inhalation administration include solutions in saline which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
- compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal,
- compositions for rectal administration include suppositories which may contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
- a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
- exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
- a "therapeutically effective" amount of an Hsp70 complex of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for an adult human of from about 0.1 to 100 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 3 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
- Preferred subjects for treatment include animals, most preferably mammalian species such as humans.
- terapéuticaally effective is meant an amount necessary to achieve a desired result, for example, alleviation of symptoms of a particular disorder in a patient, the improvement of an ascertainable measurement associated with a particular disorder, or the prevention of a particular immune response.
- a desired result for example, alleviation of symptoms of a particular disorder in a patient, the improvement of an ascertainable measurement associated with a particular disorder, or the prevention of a particular immune response.
- the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
- Preferred subjects for treatment include animals, most preferably mammalian species such as humans.
- Hsp70 complexes of the present invention may be employed alone or in combination with each other and/or other suitable therapeutic agents, such as antiinflammatories, antiproliferatives, chemotherapeutic agents, and immunosuppres s ants .
- suitable therapeutic agents such as antiinflammatories, antiproliferatives, chemotherapeutic agents, and immunosuppres s ants .
- Hsp70 fusion proteins were generated by PCR amplification of human Hsp70 DNA sequences using primers corresponding to the published sequence and including restriction endonuclease sites to enable directed cloning into a prokaryotic expression vector, ProExHta (Life Technologies, Inc.).
- NF-kB p50 sequences were generated in the same way, using primers corresponding to the published p50 sequence and cloned upstream of (5' to) Hsp70 sequences in the same expression vector.
- the cloning vector included a 6x His tag for use in purification of expressed protein over a metal column.
- DNA was transformed into a bacterial host and protein expression was induced using IPTG. Soluble, expressed fusion protein was purified using conventional affinity purification techniques and subsequently used for the following experiments.
- Hsp70-FITC or BSA-FITC as a control
- peripheral blood B cells were resistant to uptake, they could be induced to transport the protein after 48 hours of activation in vitro with anti-CD40 plus anti-Ig antibodies.
- This method of B cell activation is known to result in the expression of various differentiation and proliferation associated genes.
- activation of peripheral blood T cells by anti-CD3 and anti-CD28 antibodies did not affect Hsp70 transport. No intracellular uptake was observed by Jurkat T cell line or HeLa fibroblast cell line, but we did observe efficient uptake by two mature B cell lines, RAJI and BJAB.
- the cell type specificity and inducibility of cellular Hsp70 uptake may reflect differential expression of a required surface or nuclear receptor for the Hsp70 protein. Studies are now in progress to investigate the surface proteins which may be involved in the binding and interaalization of extracellular Hsp70.
- Hsp70-FITC was not saturable in the concentration range we used (35 nM-1 ⁇ M), indicative of a high capacity receptor-mediated uptake mechanism. In addition, internalization could not be blocked by preincubation with a 10-fold excess of unlabeled Hsp70.
- the 244 amino acid polypeptide has the following sequence:
- the 92 amino acid polypeptide has the following sequence:
- TNF ⁇ production is another example of an inflammatory response also largely regulated by NF- ⁇ B.
- the internalized fusion protein was also able to induce TNF ⁇ production by human peripheral blood lymphocytes (Figure 7B).
- Freshly isolated PBLs were incubated with LPS or Hsp70-p50 for 6 hours, after which time supernatants were collected and tested for cytokine levels by ELISA. Again, we found the fusion proteins to be as effective as LPS in inducing TNF ⁇ production, and established that intact protein was responsible for activation by showing that heat denaturation of the fusion protein abolished the effect.
- Hsp70-p50 fusion proteins Two p50 fusion proteins were constructed using the nucleotide sequence corresponding to amino acids 1-406 of the NF- ⁇ B pi 05 subunit protein. This sequence includes the DNA binding domain as well as the rel homology domain. The two fusion proteins varied in the length of Hsp70 fragment used. The two Hsp70 sequences were both derived from the C-terminus, including either the terminal 276 or 735 nucleotides, which correspond to a 10 kD (the 92 amino acid polypeptide discussed above) and a 28 kD (the 244 amino acid polypeptide discussed above) protein fragment.
- Hsp70/10-p50 or Hsp70/28-p50 Either the 10 kD or the 28 kD Hsp70 protein was fused C-terminal to the p50 protein, and the resulting fusion proteins were denoted Hsp70/10-p50 or Hsp70/28-p50, respectively.
- the prokaryotic expression vector ProEX HT (Life Technologies, Gaithersburg, MD) was used for cloning, expression and purification, as per the manufacturer's recommendations . Confocal laser scanning microscopy.
- Cells were typically treated with 10 ⁇ g/ml FITC-conjugated proteins or as indicated in the text for one hour at 37°C followed by a ash in PBS, fixation in 2% paraformaldehyde, an additional wash in PBS and subsequent visual analysis by confocal microscopy (Bio-Rad, Hercules, CA) using Molecular Dynamics LaserSharp software and Adobe Photoshop. Western blot analysis of imported Hsp70-p50 fusion proteins. Cells were treated with FITC-conjugated proteins for one hour at 37°C, washed in PBS and used for preparation of nuclear extracts. Equal protein amounts were separated by SDS- PAGE.
- oligonucleotides (Promega, Madison, WI) were end labeled with [ ⁇ - 32 P]ATP and T4 kinase. The conditions for binding reactions with oligonucleotide probes were as previously described.
- I ⁇ ununo fluorescence assay FACS
- 70Z/3 cells were treated with either 30 ⁇ g/ml Hsp70/10-p50 fusion protein or 100 ng/ml LPS and incubated overnight at 37°C. Cells were then washed in PBS and fixed in 2% paraformaldehyde prior to staining with FITC-conjugated anti-kappa antibody. After an additional PBS wash, cells were subjected to imaging and analysis on the FACSTAR.
- TNF ⁇ assay Human peripheral blood lymphocytes were isolated as previously described and treated with 40 ⁇ g/ml Hsp70 fusion protein or LPS for 6 hours. Supernatants were collected and analyzed for TNF ⁇ by ELISA (Genzyme, Cambridge, MA).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000583940A JP4892132B2 (en) | 1998-11-24 | 1999-11-17 | Intracellular targeted transport of compounds by 70 kD heat shock protein |
CA2352286A CA2352286C (en) | 1998-11-24 | 1999-11-17 | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
DK99960422T DK1133517T3 (en) | 1998-11-24 | 1999-11-17 | Intranuclear targeted transport of compounds using 70 kd heat shock protein |
EP99960422A EP1133517B1 (en) | 1998-11-24 | 1999-11-17 | INTRANUCLEAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
DE69941156T DE69941156D1 (en) | 1998-11-24 | 1999-11-17 | INTRANUCLEAR, TRANSPORT OF CONNECTIONS THROUGH THE 70KD HEAT SHOCK PROTEIN |
AU17314/00A AU760081B2 (en) | 1998-11-24 | 1999-11-17 | Intracellular targeted delivery of compounds by 70 kD heat shock protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10987298P | 1998-11-24 | 1998-11-24 | |
US60/109,872 | 1998-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000031113A1 true WO2000031113A1 (en) | 2000-06-02 |
Family
ID=22330008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027244 WO2000031113A1 (en) | 1998-11-24 | 1999-11-17 | INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1133517B1 (en) |
JP (1) | JP4892132B2 (en) |
AU (1) | AU760081B2 (en) |
CA (1) | CA2352286C (en) |
CY (1) | CY1110350T1 (en) |
DE (1) | DE69941156D1 (en) |
DK (1) | DK1133517T3 (en) |
ES (1) | ES2327986T3 (en) |
PT (1) | PT1133517E (en) |
WO (1) | WO2000031113A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022656A2 (en) * | 2000-09-13 | 2002-03-21 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
WO2003082346A1 (en) * | 2002-04-02 | 2003-10-09 | 'asgl-Farmatsevticheskie Innovatsii', Zakrytoe Aktsionernoe Obschestvo | Recombinant chimeric protein for the target delivery of dna to eukariotic target cells |
WO2006020743A2 (en) * | 2004-08-13 | 2006-02-23 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
WO2009036349A1 (en) * | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
US8071533B2 (en) | 2006-03-20 | 2011-12-06 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for modulating store-operated calcium entry |
WO2013070529A1 (en) | 2011-11-09 | 2013-05-16 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between cftr and cal |
WO2016156536A1 (en) | 2015-03-31 | 2016-10-06 | Universite Pierre Et Marie Curie (Paris 6) | Pro-apoptotic set and pp2a peptides |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US10781254B2 (en) | 2010-03-26 | 2020-09-22 | The Trustees Of Dartmouth College | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11097015B2 (en) | 2018-10-10 | 2021-08-24 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
US11529416B2 (en) | 2012-09-07 | 2022-12-20 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2643468T3 (en) * | 2010-11-22 | 2018-11-30 | Amicus Therapeutics, Inc. | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08510756A (en) * | 1993-06-04 | 1996-11-12 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | Stress proteins and their use |
ATE318899T1 (en) * | 1996-11-26 | 2006-03-15 | Stressgen Biotechnologies Corp | FUSION PROTEINS INCLUDING STRESS PROTEINS FOR PRODUCING AN IMMUNE RESPONSE |
-
1999
- 1999-11-17 CA CA2352286A patent/CA2352286C/en not_active Expired - Fee Related
- 1999-11-17 DK DK99960422T patent/DK1133517T3/en active
- 1999-11-17 ES ES99960422T patent/ES2327986T3/en not_active Expired - Lifetime
- 1999-11-17 AU AU17314/00A patent/AU760081B2/en not_active Ceased
- 1999-11-17 JP JP2000583940A patent/JP4892132B2/en not_active Expired - Fee Related
- 1999-11-17 EP EP99960422A patent/EP1133517B1/en not_active Expired - Lifetime
- 1999-11-17 WO PCT/US1999/027244 patent/WO2000031113A1/en active IP Right Grant
- 1999-11-17 PT PT99960422T patent/PT1133517E/en unknown
- 1999-11-17 DE DE69941156T patent/DE69941156D1/en not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100975T patent/CY1110350T1/en unknown
Non-Patent Citations (18)
Title |
---|
DANG ET AL: "Nuclear and nucleolar targeting sequences of c-erb-A, c-myh, N-myc, p53, HSP70 and HIV tat proteins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 30, 25 October 1989 (1989-10-25), pages 18019 - 18023, XP002923303 * |
ELLIOTT, CELL, vol. 88, 1997, pages 223 - 233 |
FAWELL, PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 664 - 668 |
FIX J.A.: "Oral controlled release technology for peptides: status and future prospects", PHARMACEUTICAL RESEARCH, vol. 13, no. 12, 1996, pages 1760 - 1764, XP002923307 * |
HAWIGER, CURR. OPIN. IMMUN., vol. 9, 1997, pages 189 - 194 |
JOHNSON ET AL: "Exogenous HSP70 becomes cell associated, but not internalized by stressed arterial smooth muscle cells", IN VITRO CELLULAR AND DEVELOPMENTAL BIOLOGY, vol. 29A, October 1993 (1993-10-01), pages 807 - 812, XP002923306 * |
LECLAIR ET AL: "The p50 subunit of NF-kB associates with the NF-IL6 transcription factor", PROC. NATL. ACAD. SCI. USA,, vol. 89, September 1992 (1992-09-01), pages 8145 - 8149, XP002923305 * |
MARGULIS ET AL: "Liposomal delivery of purified heat shock protein hsp70 into rat pancreatic islets as protection against interleukin 1beta-induced impaired beta-cell function", DIABETES, vol. 40, November 1991 (1991-11-01), pages 1418 - 1422, XP002923302 * |
MILNER, C.M.; CAMPBELL, R.D., IMMUNOGENETICS, vol. 32, 1990, pages 242 - 251 |
PERKINS ET AL: "Distinct combination of NF-kB subunits determine the specificity of transcriptional activation", PROC. NATL. ACAD. SCI. USA,, vol. 89, March 1992 (1992-03-01), pages 1529 - 1533, XP002923304 * |
PHELAN, NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 440 - 443 |
POOGA, FASEB J., vol. 12, 1998, pages 67 - 77 |
ROJAS, NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 370 - 375 |
ROMAN, IMMUNOLOGY, vol. 88, 1996, pages 487 - 492 |
See also references of EP1133517A4 |
SUZUE, J. IMMUNOL., vol. 156, 1996, pages 873 - 879 |
TAKAKURA ET AL: "Macromolecular carrier systems for targeted drug delivery: pharmacokinetic consideration on biodistribution", PHARMACEUTICAL RESEARCH, vol. 13, no. 6, 1996, pages 820 - 831, XP002923301 * |
VIVES, J. BIOL. CHEM., vol. 272, 1997, pages 16010 - 16017 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022656A3 (en) * | 2000-09-13 | 2002-09-26 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
US7517948B2 (en) | 2000-09-13 | 2009-04-14 | Multimmune Gmbh | Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof |
WO2002022656A2 (en) * | 2000-09-13 | 2002-03-21 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
WO2003082346A1 (en) * | 2002-04-02 | 2003-10-09 | 'asgl-Farmatsevticheskie Innovatsii', Zakrytoe Aktsionernoe Obschestvo | Recombinant chimeric protein for the target delivery of dna to eukariotic target cells |
WO2006020743A2 (en) * | 2004-08-13 | 2006-02-23 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
WO2006020743A3 (en) * | 2004-08-13 | 2006-07-20 | Gen Electric | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
US8071533B2 (en) | 2006-03-20 | 2011-12-06 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for modulating store-operated calcium entry |
WO2009036349A1 (en) * | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US10781254B2 (en) | 2010-03-26 | 2020-09-22 | The Trustees Of Dartmouth College | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
WO2013070529A1 (en) | 2011-11-09 | 2013-05-16 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between cftr and cal |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US11752189B2 (en) | 2012-06-22 | 2023-09-12 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
US11529416B2 (en) | 2012-09-07 | 2022-12-20 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
WO2016156536A1 (en) | 2015-03-31 | 2016-10-06 | Universite Pierre Et Marie Curie (Paris 6) | Pro-apoptotic set and pp2a peptides |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US11987630B2 (en) | 2016-02-12 | 2024-05-21 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
US11603402B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11603403B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11649283B2 (en) | 2016-04-15 | 2023-05-16 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11097015B2 (en) | 2018-10-10 | 2021-08-24 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
DK1133517T3 (en) | 2009-11-23 |
ES2327986T3 (en) | 2009-11-05 |
EP1133517A4 (en) | 2003-01-08 |
DE69941156D1 (en) | 2009-09-03 |
EP1133517A1 (en) | 2001-09-19 |
CA2352286A1 (en) | 2000-06-02 |
EP1133517B1 (en) | 2009-07-22 |
AU1731400A (en) | 2000-06-13 |
JP4892132B2 (en) | 2012-03-07 |
AU760081B2 (en) | 2003-05-08 |
CA2352286C (en) | 2011-07-12 |
PT1133517E (en) | 2009-08-12 |
CY1110350T1 (en) | 2015-04-29 |
JP2002530426A (en) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1133517B1 (en) | INTRANUCLEAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN | |
Zou et al. | Progress in research and application of HIV-1 TAT-derived cell-penetrating peptide | |
Fischer et al. | Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation | |
US7514530B2 (en) | Peptide carrier for delivering siRNA into mammalian cells | |
US10131888B2 (en) | Intracellular protein delivery | |
KR20030025901A (en) | Cell permeable peptides for inhibition of inflammatory reactions and methods of use | |
JPH03200800A (en) | Novel protein-polycation composite | |
JPH05506991A (en) | Novel protein-polycation conjugate | |
US10206976B2 (en) | Protein particles comprising disulfide crosslinkers and uses related thereto | |
JPH11505805A (en) | Compositions containing nucleic acids and ligands for therapeutic treatment | |
JPH09510352A (en) | Heparin-binding growth factor for gene therapy and anterior eye disease | |
US20210169920A1 (en) | Compositions and methods of modulating hif-2a to improve muscle generation and repair | |
CA3040645A1 (en) | Peptide-based non-proteinaceous cargo delivery | |
US6730302B1 (en) | Intracellular targeted delivery of compounds by 70 kD heat shock protein | |
JP2020072716A (en) | Novel cell-penetrating compositions and methods using the same | |
TW201514200A (en) | Artificial transcription factors for the treatment of diseases caused by OPA1 haploinsufficiency | |
JP2013071904A (en) | Peptide having anti-influenza virus activity | |
JP6758022B2 (en) | Vascular endothelial cell growth factor receptor inhibitor peptide | |
Beerens | Intercellular spread of the transgene product to improve the efficiency of cancer gene therapy | |
TW201441249A (en) | Artificial transcription factors and their use for the treatment of maladapted wound healing in the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17314 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 583940 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2352286 Country of ref document: CA Ref country code: CA Ref document number: 2352286 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17314/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999960422 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960422 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 17314/00 Country of ref document: AU |